MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
If you are a long-term stockholder in Marinus between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) on behalf of long-term stockholders following a class action complaint that was filed against Marinus on June 5, 2024 with a Class Period from March 17, 2021 and May 7, 2024. Our investigation concerns whether the board of directors of Marinus have breached their fiduciary duties to the company.
According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
If you are a long-term stockholder of Marinus, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Dell, Nvidia, and Elastic Join Forces to Supercharge AI Workloads
Aug 12 - Dell Technologies (NYSE:DELL) is teaming up with Nvidia (NASDAQ:NVDA) and Elastic (NYSE:ESTC) to supercharge its AI Data Platform, designed for industries from media and entertainment to finance. The goal is to make it easier for enterprises to build, deploy, and scale AI at lightning speed. Dell's Vrashank Jain calls the platform built for a world where data is gold, pointing to its ability to break down data silos, accelerate workflows, and create richer AI-enabled experiences. Under the hood, Dell PowerEdge R7725 servers paired with Nvidia's RTX PRO 6000 Blackwell Server Edition GPUs deliver serious computing muscle. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Elastic brings its Elasticsearch tech to the table, enabling natural language and vector search. Editors can now pinpoint a scene instantly without digging through endless folders. Nvidia's Omniverse libraries and AI models take it further, streamlining searches through massive 3D asset libraries. Whether in film production or real-time financial analytics, Dell claims the platform accelerates processing, communication and storage of low-latency, high-performance AI workloads. This tripartite co-operation could be a shortcut to greater AI-based efficiency that companies crave. This article first appeared on GuruFocus.
Yahoo
2 minutes ago
- Yahoo
Delta, Aeromexico request extension to wrap up antitrust agreement
MEXICO CITY (Reuters) -Carriers Delta and Aeromexico on Tuesday argued against winding down their antitrust agreement, as proposed by the U.S. Department of Transportation, while asking for an extension to do so if needed. The two, in a filing to authorities, requested the deadline be extended to March 28 of next year, the end of the sector's "winter season," from the current October 25. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- North America Leads Today, Asia Pacific to Record Fastest GrowthThe global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now?HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders?The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders?The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market OutlookAs automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities:Drug Screening MarketCarrier Screening MarketCell based Assays MarketLabel Free Detection MarketLife Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
